| Date | Title | Description |
| 13.01.2026 |
Amgen CEO says weight loss drug can address ‘patient persistence issue’ | Monday - Friday, 6:00 - 7:00 PM ET
Amgen CEO Bob Bradway told CNBC’s Jim Cramer he thinks his company’s obesity drug can help patients maintain weight loss, which he indicated is a challenge.
“We think we can address one of the reasons that... |
| 07.02.2024 | The GLP-1 panic is alive and well | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, all. Damian here with news of a new biotech venture fund, a bold bet against a billion-dollar deal, an... |
| 09.11.2022 | Arrowhead Gets $250M in Royalty Deal for Cardio Drug Heading to Phase 3 | Arrowhead Pharmaceuticals is turning its financial tie to a promising but still experimental heart drug into $250 million in immediate cash, a move that comes days after the reporting of Phase 2 data showing the therapy successfully reduced... |
| 22.09.2021 | Amgen : Investor Presentation September 2021 | INVESTOR PRESENTATION
SEPTEMBER 2021
SAFE HARBOR STATEMENT
This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are ... |
| 26.08.2021 | Amgen : Investor Presentation August 2021 | INVESTOR PRESENTATION
AUGUST 2021
SAFE HARBOR STATEMENT
This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are sta... |
| 01.06.2021 | Eying eczema, Amgen pays $400M to co-develop Phase 3-ready Kyowa Kirin drug | Amgen is vying to bolster its immunology drug portfolio and it is paying $400 million to do it. The sum gives it a share of an antibody from Kyowa Kirin that offers a new way of treating atopic dermatitis and potentially other inflammatory ... |
| 18.05.2021 | AMGEN INC.
Amgen : 2021 Annual Meeting of Stockholders Presentation | 2021
Annual Meeting of Stockholders
May 18, 2021
RECONCILIATIONS
Amgen Inc.
GAAP to Non-GAAP Reconciliations (Dollars In millions)
(Unaudited)
Years ended
December 31,
2020 2019
GAAP cost of sales $ 6,159 $ 4,356
Adjustments to cost of sale... |
| 31.03.2021 | UPDATED: Biotech pioneer and startup investor John Martin, who built Gilead into a powerhouse player, has died | With blockbuster immunology meds Enbrel and Otezla already in the fold, Amgen has mostly stood pat on infusing new blood into its legacy pipeline. But that success won’t last forever, and Amgen is taking a far-looking bet on a private biote... |
| 31.03.2021 | UPDATED: Biotech pioneer and startup investor John Martin, who built Gilead into a powerhouse player, has died | BridgeBio $BBIO is on a roll.
At the end of February, they won an approval for their first drug, a therapy used to treat extremely rare cases of molybdenum cofactor deficiency type A. In the middle of the month, there was positive proof-of-... |
| 30.03.2021 | After pilot project, Takeda inks $500M pact to tap into a Kevan Shokat protégé's covalent small molecule fishing platform | As new technologies open up new avenues toward targets widely considered undruggable by small molecules, Takeda is taking a chance on a low-profile drug discovery player with promises of up to $500 million in biobucks.
P... |
| 30.03.2021 | Novartis dives even deeper into radioligands, notching licensing deal with iTheranostics for multiple compounds | Novartis captured attention last week for its Phase III prostate cancer win with a radioligand therapy it picked up for $2 billion back in 2018. Now, Novartis is doubling down on the field.
Novartis will acquire develop... |
| 16.02.2021 | Weeks after dropping big response data, Amgen lines up priority review for KRAS hopeful sotorasib in NSCLC | Amgen is looking to go where no other drugmaker has gone before with the KRAS inhibitor sotorasib, which posted big Phase II lung cancer response data in late January. The FDA has been listening, and now it’s ready to give ... |
| 23.12.2020 | Amgen hands off rights to leprosy, tuberculosis med picked up as part of $13.4B Otezla deal | Amgen scored a big pickup with its acquisition of immunology blockbuster Otezla from Bristol Myers Squibb late last year. But that deal also came with a molecule for tuberculosis and leprosy with significantly less c... |
| 02.07.2018 | AbbVie spent billions on a buzzy Silicon Valley cancer drug company. Now Wall Street's calling the deal a 'dud.' | Flickr/Ed Uthman
Advertisement
The cancer-stem-cell company Stemcentrx was one of the biggest venture capital-backed deals in history when it was acquired in 2016 for over $10 billion. But it hasn't seen the blockbuster success its big pric... |
| 12.12.2017 | Ex-Dezima CEO co-founds NASH startup, flying into Phase IIB with €25 million | Rob de Ree
A new Dutch biotech, co-founded and led by the former CEO of Dezima, is launching with €25 million in startup capital from prominent European investors to develop an oral drug for NASH.
The Series A round was led ... |
| 30.10.2017 | Bristol-Myers, J&J sink cash into a new $95M European biotech fund | A venture capital firm in the Netherlands — backed by some big names in Big Pharma — has raised $95 million in a new fund to fuel European biotech startups.
The Dutch VC firm, called BioGeneration Ventures (BGV), plans to sin... |
| 02.05.2017 | Globalized genomics: WuXi NextCODE raises $75M Series B | In an email forwarded by a company representative, WuXi NextCODE CEO Hannes Smarason said the products were the first of their kind in the region.
“Our China products give patients and consumers access to global quality genomic testing and ... |
| 25.04.2017 | With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact | Five months after Amgen and Novartis outlined their second batch of positive Phase III data for their CGRP migraine drug erenumab, the two giants have reworked their commercial partnership to give Novartis a piece of the ... |
| 16.11.2016 | Bristol-Myers partners with Enterome on a gut-level approach to immuno-oncology; MorphoSys adds $126M | Carl Decicco, Bristol-Myers Squibb
Bristol-Myers Squibb has turned to Paris-based microbiome expert Enterome for its latest immuno-oncology partnership. The biotech landed a $15 million upfront and unspecified, res... |
| 26.10.2016 | Genomics Medicine Ireland raises $40 million for large-scale genomic research | Irish Taoiseach (Prime Minister) Enda Kenny formally announced the news, highlighting the local economic impact he believes GMI could have.
“When the Government established the ISIF, we wanted to encourage new investment and job creation ac... |
| 27.09.2016 | Amgen hit with a setback as Kyprolis fails a key frontline trial for multiple myeloma | Sean Harper, Executive Vice President, Research and Development
Amgen reported early Tuesday that Kyprolis has failed a Phase III trial for frontline use against multiple myeloma, a setback that can only further shar... |
| 27.10.2015 | Herpes virus that attacks cancer is first of new viral therapies | Viruses are usually thought of as agents of disease. But for the first time, scientists are poised to bring to the US market a virus that can help thwart cancer, a development that could herald a new age of viral therapies.
Approved by the ... |
| 17.12.2008 | KAI Pharmaceuticals Initiates Phase 2b Clinical Study of KAI-9803 in Heart Attack Patients | Learn More-External Link |
| 10.12.2008 | KAI-1678, First-in-Class Compound, Enters Phase 2a Clinical Testing for the Treatment of Pain | Learn More-External Link |
| - | Eying eczema, Amgen pays $400M to co-develop Phase 3-ready Kyowa Kirin drug | Amgen is vying to bolster its immunology drug portfolio and it is paying $400 million to do it. The sum gives it a share of an antibody from Kyowa Kirin that offers a new way of treating atopic dermatitis and potentially other inflammatory ... |
| - | Genomics Medicine Ireland raises $40 million for large-scale genomic research | GMI Co-Founders, Dan Crowley, Paul Thurk, Sean Ennis, Maurice Treacy and Irish PM, Enda Kenny
The 4.7 million-strong Irish population will soon be under the genomic microscope, following a $40 million series A funding round by Genomics Medi... |
| - | Globalized genomics: WuXi NextCODE raises $75M Series B | WuXi NextCODE, a so-called contract genomics organization (CGO), has raised $75 million in a new Series B financing round co-led by Temasek Holdings and Yunfeng Capital — a Chinese private equity firm cofounded by Ali Baba billionaire Jack ... |
